Sly Saint
Senior Member (Voting Rights)
"PHILADELPHIA, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American:HEB) announced today its financial results for the third quarter ended September 30, 2017."
"We have secured our first country approval for Ampligen® in ME/CFS and we expect several more in the coming years."
"Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)."
http://ir.hemispherx.net/profiles/i...ryID=86477&BzID=2265&g=980&Nav=0&LangID=1&s=0
eta: see also http://scr.zacks.com/News/Press-Rel...ause-A-Turnaround-For-Hemispherx/default.aspx
"We have secured our first country approval for Ampligen® in ME/CFS and we expect several more in the coming years."
"Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)."
http://ir.hemispherx.net/profiles/i...ryID=86477&BzID=2265&g=980&Nav=0&LangID=1&s=0
eta: see also http://scr.zacks.com/News/Press-Rel...ause-A-Turnaround-For-Hemispherx/default.aspx